

Immuno-Oncology Biologics: Process for Setting Coverage

Bryan Loy, MD, MBA
Vice President of Oncology, Laboratory
and Personalized Medicine
Humana Inc.

2.4.16
12 PM EST
E-course 10



INSTITUTE
FOR CLINICAL
IMMUNO-ONCOLOGY



accc-iclio.org

Oncology coverage policy

- Evaluation of evidence and the role of technology assessment
- Coverage for parenteral biologics under the medical benefit
- Integration of medical benefit (parenteral) and pharmacy benefit (orals) policies
- Communication of coverage policies



Physician and patient demand for immuno-oncology agents

- Coverage and payment for FDA approved indications
- Coverage and payment for off-label uses and the bases for such coverage
 - NCCN Guidelines/Compendium, other compendia
 - Humana processes
- Keeping up with demand for off-label uses
 - NCCN recommended
 - Beyond NCCN recommended

Ongoing challenges and special programs and processes

Challenges

- Rapid expansion of indications (e.g., renal cell, Hodgkin's Disease, Head and Neck)
- The advent of combinations and how to manage utilization



Programs and processes

- Role of New Century Health, Oncology Analytics
- Implementation of specific payment methods

Questions?



AN
INSTITUTE
OF ACCC



Thank You

Save-the-Date
ICLIO National Conference
September 30, 2016
Philadelphia

www.accc-iclio.org



INSTITUTE
FOR CLINICAL
IMMUNO-ONCOLOGY

AN INSTITUTE OF
ACCC
Association of Community Cancer Centers